JP2012530694A - 薬物のナノ分散体およびその調製のための方法 - Google Patents
薬物のナノ分散体およびその調製のための方法 Download PDFInfo
- Publication number
- JP2012530694A JP2012530694A JP2012515633A JP2012515633A JP2012530694A JP 2012530694 A JP2012530694 A JP 2012530694A JP 2012515633 A JP2012515633 A JP 2012515633A JP 2012515633 A JP2012515633 A JP 2012515633A JP 2012530694 A JP2012530694 A JP 2012530694A
- Authority
- JP
- Japan
- Prior art keywords
- nanodispersion
- acid
- salts
- surfactant
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Dispersion Chemistry (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
本発明の目的は、非経口または経口の経路による投与の前、および間に所望の期間にわたって安定である薬物のナノ分散体を提供することである。
A.水混和性溶媒および水を含むビヒクル中に分散された、300nm未満の平均径を有するナノ粒子を含むナノ分散体であって、このナノ粒子は、1つ以上の薬物、ポリマーおよびサーファクタントを含み、このサーファクタントは、脂肪酸類またはその塩と、ステロールあるいはその誘導体またはその塩との混合物を含む。
本発明は、水混和性溶媒および水を含む水性のビヒクル中に分散された、300nm未満の平均径を有するナノ粒子を含むナノ分散体であって、このナノ粒子が、薬物、ポリマーおよびサーファクタントを含み、このサーファクタントが、脂肪酸類またはその塩と、ステロールあるいはその誘導体またはその塩との混合物を含むナノ分散体を提供する。
K−値 平均分子量
15 約10,000
30 約40,000
60 約160,000
90 約360,000
1)治療上活性な成分(および/または他の薬剤)、ポリマー、ならびに脂肪酸類またはその塩、ステロールあるいはその誘導体またはその塩およびそれらの混合物から選択されるサーファクタントを、エタノールおよび/またはPEGなどの水混和性溶媒中に、攪拌および加熱しながら溶解させ、薬物の濃縮溶液を得る。このように得られた溶液を、メンブランフィルターで濾過する。この溶液に、水性液体ビヒクル(5%デキストロース溶液)をゆっくりと加え、混合物を振盪/攪拌し、これによって本発明のナノ分散体の形成をもたらす。このように形成されたナノ分散体を、必要に応じて均質化および/または超音波処理し、濾過または凍結乾燥する。薬品の凍結乾燥された粉末を、水性媒体により再構成して、患者へ投与する前に本発明のナノ分散体を再形成してもよい。
Claims (17)
- 水混和性溶媒および水を含むビヒクル中に分散された、300nm未満の平均径を有するナノ粒子を含む安定なナノ分散体であって、該ナノ粒子は、1つ以上の薬物を含み、該薬物はポリマーおよびサーファクタントを有し、該サーファクタントは、脂肪酸類またはその塩と、ステロールあるいはその誘導体またはその塩との混合物を含む、ナノ分散体。
- 前記薬物が、テムシロリムス、タクロリムス、シロリムス、フェノフィブラート、シクロスポリン、タクロリムス、ブリンゾラミドまたはその医薬上許容される塩からなる群より選択される、請求項1に記載のナノ分散体。
- 前記サーファクタント対薬物の比が、約1:5〜1:10であり、かつ該ナノ分散体が少なくとも4時間安定である、請求項2に記載のナノ分散体。
- 前記サーファクタント対薬物の比が、約1:5〜約1:10であり、かつ該ナノ分散体が24時間安定である、請求項3に記載のナノ分散体。
- 前記サーファクタント対薬物の比が、約1:10であり、かつ該ナノ分散体が8時間安定である、請求項4に記載のナノ分散体。
- 前記ナノ粒子の平均径が約10nm〜約200nmの範囲である、請求項5に記載のナノ分散体。
- 前記水混和性溶媒が、アルコール、グリコールおよびその誘導体、ポリアルキレングリコールおよびその誘導体、グリセロール、グリコフロールならびにそれらの組み合わせから選択される、請求項6に記載のナノ分散体。
- 前記水混和性溶媒が、アルコールおよびポリエチレングリコール(PEG)からなる群より選択される、請求項7に記載のナノ分散体。
- 前記ポリマーが水溶性のポリマーである、請求項8に記載のナノ分散体。
- 前記水溶性のポリマーが、ポリビニルピロリドンおよびポリエチレングリコールからなる群より選択される、請求項9に記載のナノ分散体。
- 用いられるポリビニルピロリドンが、1000〜約50,000という範囲の分子量を有し、かつ0.001%(w/v)〜10%(w/v)の範囲の量で用いられる、請求項9に記載のナノ分散体。
- 前記脂肪酸類またはその塩が、カプリル酸、オレイン酸、ステアリン酸およびそれらの混合物からなる群より選択される、請求項11に記載のナノ分散体。
- 前記ステロールあるいはその誘導体またはその塩が、コレステロール、極性の酸のコレステリルエステル、植物ステロール、胆汁酸、それらの誘導体、それらの塩および混合物からなる群より選択される、請求項12に記載のナノ分散体。
- 前記極性の酸が、コハク酸、ヘミコハク酸、硫酸、リン酸、グルタミン酸およびアスパラギン酸、ホウ酸からなる群より選択される、請求項13に記載のナノ粒子。
- 前記サーファクタントが、約0.001%(w/v)〜約5.0%(w/v)の範囲の量で用いられる、請求項14に記載のナノ分散体。
- 水混和性溶媒中に1つ以上の薬物、ポリマーおよびサーファクタントを含み、該サーファクタントが、脂肪酸類またはその塩とステロールあるいはその誘導体またはそれらの塩との混合物を含む溶液であって、水性液体ビヒクルでの希釈の際にナノ分散体を生じる、溶液。
- 300nm未満の平均粒子径を有するナノ粒子であって、1つ以上の薬物、サーファクタントおよびポリマーを含み、該サーファクタントが、脂肪酸またはその塩とステロールあるいはその誘導体またはその塩との混合物を含む、ナノ粒子。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1468/MUM/2009 | 2009-06-19 | ||
IN1468MU2009 | 2009-06-19 | ||
PCT/IN2010/000423 WO2010146606A1 (en) | 2009-06-19 | 2010-06-18 | Nanodispersion of a drug and process for its preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012530694A true JP2012530694A (ja) | 2012-12-06 |
JP5627039B2 JP5627039B2 (ja) | 2014-11-19 |
Family
ID=43355961
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012515633A Active JP5627039B2 (ja) | 2009-06-19 | 2010-06-18 | 薬物のナノ分散体およびその調製のための方法 |
Country Status (12)
Country | Link |
---|---|
US (1) | US8778364B2 (ja) |
EP (1) | EP2442805A4 (ja) |
JP (1) | JP5627039B2 (ja) |
KR (1) | KR20120050414A (ja) |
CN (1) | CN102802624A (ja) |
AR (1) | AR077155A1 (ja) |
AU (1) | AU2010261342A1 (ja) |
CA (1) | CA2765541A1 (ja) |
EA (1) | EA201270050A1 (ja) |
MX (1) | MX2011013726A (ja) |
WO (1) | WO2010146606A1 (ja) |
ZA (1) | ZA201109510B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016516765A (ja) * | 2013-04-12 | 2016-06-09 | ビョーメ バイオサイエンシズ ピーブイティー.リミテッド | 抗菌薬の組成物および製剤、その製造法および微生物感染症の治療方法 |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101752944B1 (ko) | 2010-05-03 | 2017-07-03 | 테이코쿠 팔마 유에스에이, 인코포레이티드 | 비수성의 탁산 프로에멀젼 제제, 및 그의 제조 및 사용 방법 |
EA030620B1 (ru) | 2010-05-26 | 2018-09-28 | Селекта Байосайенсиз, Инк. | Композиции для выработки иммунного ответа к наборам поверхностных антигенов, содержащие синтетические наноносители, и их применение |
WO2012061717A1 (en) | 2010-11-05 | 2012-05-10 | Selecta Biosciences, Inc. | Modified nicotinic compounds and related methods |
CN104105472A (zh) | 2011-12-20 | 2014-10-15 | 维奥姆生物科学有限公司 | 用于治疗真菌感染的局部油组合物 |
CN103483353B (zh) * | 2012-06-13 | 2016-02-24 | 上海现代药物制剂工程研究中心有限公司 | 二硫杂环戊烯并吡咯酮化合物的纳米粒及制备方法 |
JO3685B1 (ar) | 2012-10-01 | 2020-08-27 | Teikoku Pharma Usa Inc | صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها |
US9446131B2 (en) | 2013-01-31 | 2016-09-20 | Merz Pharmaceuticals, Llc | Topical compositions and methods for making and using same |
AU2015246030B2 (en) * | 2014-04-09 | 2020-03-12 | Pulse Pharmaceuticals Pvt Ltd | Composition and method of producing nanoformulation of water insoluble bioactives in aqueous base |
US20170099833A1 (en) * | 2014-05-30 | 2017-04-13 | Oms Investments, Inc. | Nano-sized water-based dispersion compositions and methods of making thereof |
CN104798772B (zh) * | 2015-03-13 | 2017-05-24 | 中国农业科学院农业环境与可持续发展研究所 | 一种农药纳米固体分散体及其制备方法 |
JP2018516964A (ja) | 2015-06-09 | 2018-06-28 | サン、ファーマ、アドバンスト、リサーチ、カンパニー、リミテッドSun Pharma Advanced Research Company Limited | 局所進行性または転移性である肝内もしくは肝外胆管または胆嚢のカルシノーマに罹患する患者を治療する方法 |
TWI709410B (zh) * | 2015-08-11 | 2020-11-11 | 荷蘭商艾西優藥物股份有限公司 | 具有生物活性親脂性化合物之聚乙二醇化脂質奈米粒子 |
WO2017053885A1 (en) | 2015-09-25 | 2017-03-30 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
WO2017129772A1 (en) * | 2016-01-29 | 2017-08-03 | Xellia Phamaceuticals Aps | Stable pharmaceutical compositions of temsirolimus |
CN114749656A (zh) * | 2020-12-28 | 2022-07-15 | 航天神舟生物科技集团有限公司 | 一种金属纳米铁/纳米铜粒子溶液及工作液的制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003508492A (ja) * | 1999-09-09 | 2003-03-04 | エラン ファーマ インターナショナル,リミティド | 非晶質シクロスポリンを含んで成るナノ粒状組成物並びに当該組成物の製造方法及び使用方法 |
JP2006508105A (ja) * | 2002-05-24 | 2006-03-09 | エラン ファーマ インターナショナル,リミティド | ナノ粒子状フィブラート製剤 |
JP2008524239A (ja) * | 2004-12-15 | 2008-07-10 | エラン ファーマ インターナショナル リミティド | ナノ粒子のタクロリムス製剤 |
JP2008531591A (ja) * | 2005-02-24 | 2008-08-14 | エラン・ファルマ・インターナショナル・リミテッド | ドセタキセルおよびそれらの類似体のナノ粒子製剤 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
US6753006B1 (en) | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
US6458373B1 (en) | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
WO1999029300A1 (en) | 1997-12-10 | 1999-06-17 | Rtp Pharma Inc. | Self-emulsifying fenofibrate formulations |
KR19990075621A (ko) | 1998-03-23 | 1999-10-15 | 임성주 | 경사 평판형 배양조 |
US6017948A (en) | 1998-10-30 | 2000-01-25 | Supergen, Inc. | Water-miscible pharmaceutical compositions |
US6365191B1 (en) | 1999-02-17 | 2002-04-02 | Dabur Research Foundation | Formulations of paclitaxel, its derivatives or its analogs entrapped into nanoparticles of polymeric micelles, process for preparing same and the use thereof |
US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
AU7599900A (en) | 1999-09-23 | 2001-04-24 | Dabur Research Foundation | Formulations of paclitaxel entrapped into nanoparticles of polymeric micelles |
AU7638200A (en) * | 1999-10-20 | 2001-04-30 | Vesifact Ag | Microemulsion preconcentrates which contain cyclosporines and corresponding microemulsions |
US7276249B2 (en) | 2002-05-24 | 2007-10-02 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
TWI230616B (en) | 2000-09-25 | 2005-04-11 | Ind Tech Res Inst | Liposome for incorporating large amounts of hydrophobic substances |
CA2445763A1 (en) | 2001-05-01 | 2002-11-07 | Angiotech Pharmaceuticals Inc. | Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions |
WO2003045357A1 (en) * | 2001-11-27 | 2003-06-05 | Transform Pharmaceuticals, Inc. | Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof |
US6780324B2 (en) | 2002-03-18 | 2004-08-24 | Labopharm, Inc. | Preparation of sterile stabilized nanodispersions |
US20040005339A1 (en) | 2002-06-28 | 2004-01-08 | Shojaei Amir H. | Formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability |
ITMI20022323A1 (it) | 2002-10-31 | 2004-05-01 | Maria Rosa Gasco | Composizioni farmaceutiche atte al trattamento di malattie oftalmiche. |
US7670627B2 (en) | 2002-12-09 | 2010-03-02 | Salvona Ip Llc | pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients |
US7345093B2 (en) | 2004-04-27 | 2008-03-18 | Formatech, Inc. | Methods of enhancing solubility of compounds |
US20050288521A1 (en) | 2004-06-29 | 2005-12-29 | Phytogen Life Sciences Inc. | Semi-synthetic conversion of paclitaxel to docetaxel |
EP2308467A3 (en) | 2005-06-17 | 2011-06-22 | Hospira Australia Pty Ltd | Liquid pharmaceutical formulations of docetaxel |
RS20080167A (en) | 2005-10-21 | 2009-07-15 | Panacea Biotec Limited, | Novel improved compositions for cancer therapy |
KR100917809B1 (ko) | 2006-05-22 | 2009-09-18 | 에스케이케미칼주식회사 | 우수한 저장안정성을 갖는 도세탁셀 함유 주사제 조성물 |
EP2076244B1 (en) | 2006-10-10 | 2016-12-07 | Jina Pharmaceuticals Inc. | Aqueous systems for the preparation of lipid-based pharmaceutical compounds; compositions, methods, and uses thereof |
US20100068251A1 (en) | 2006-10-10 | 2010-03-18 | Jina Pharmaceuticals, Inc. | Aqueous Systems For The Preparation Of Lipid Based Pharmaceutical Compounds; Compositions, Methods, And Uses Thereof |
WO2008144355A2 (en) | 2007-05-17 | 2008-11-27 | Morton Grove Pharmaceuticals, Inc. | Stable, self-microemulsifying fenofibrate compositions |
BRPI0821514B8 (pt) * | 2007-12-24 | 2021-05-25 | Sun Pharma Advanced Res Co Ltd | nanodispersão |
US20100151037A1 (en) * | 2008-08-07 | 2010-06-17 | Yivan Jiang | Method for the preparation of nanoparticles containing a poorly water-soluble pharmaceutically active compound |
-
2010
- 2010-06-18 US US13/378,758 patent/US8778364B2/en active Active
- 2010-06-18 EP EP10789111A patent/EP2442805A4/en not_active Withdrawn
- 2010-06-18 EA EA201270050A patent/EA201270050A1/ru unknown
- 2010-06-18 CN CN2010800270138A patent/CN102802624A/zh active Pending
- 2010-06-18 AU AU2010261342A patent/AU2010261342A1/en not_active Abandoned
- 2010-06-18 MX MX2011013726A patent/MX2011013726A/es not_active Application Discontinuation
- 2010-06-18 JP JP2012515633A patent/JP5627039B2/ja active Active
- 2010-06-18 KR KR1020117030828A patent/KR20120050414A/ko not_active Application Discontinuation
- 2010-06-18 CA CA2765541A patent/CA2765541A1/en not_active Abandoned
- 2010-06-18 WO PCT/IN2010/000423 patent/WO2010146606A1/en active Application Filing
- 2010-06-22 AR ARP100102179A patent/AR077155A1/es unknown
-
2011
- 2011-12-22 ZA ZA2011/09510A patent/ZA201109510B/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003508492A (ja) * | 1999-09-09 | 2003-03-04 | エラン ファーマ インターナショナル,リミティド | 非晶質シクロスポリンを含んで成るナノ粒状組成物並びに当該組成物の製造方法及び使用方法 |
JP2006508105A (ja) * | 2002-05-24 | 2006-03-09 | エラン ファーマ インターナショナル,リミティド | ナノ粒子状フィブラート製剤 |
JP2008524239A (ja) * | 2004-12-15 | 2008-07-10 | エラン ファーマ インターナショナル リミティド | ナノ粒子のタクロリムス製剤 |
JP2008531591A (ja) * | 2005-02-24 | 2008-08-14 | エラン・ファルマ・インターナショナル・リミテッド | ドセタキセルおよびそれらの類似体のナノ粒子製剤 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016516765A (ja) * | 2013-04-12 | 2016-06-09 | ビョーメ バイオサイエンシズ ピーブイティー.リミテッド | 抗菌薬の組成物および製剤、その製造法および微生物感染症の治療方法 |
KR101862448B1 (ko) * | 2013-04-12 | 2018-05-29 | 바이옴 바이오사이언스 피브이티. 엘티디. | 항균제의 조성물과 제제, 그 공정, 및 세균 감염을 치료하는 방법 |
Also Published As
Publication number | Publication date |
---|---|
KR20120050414A (ko) | 2012-05-18 |
CA2765541A1 (en) | 2010-12-23 |
US20120087959A1 (en) | 2012-04-12 |
JP5627039B2 (ja) | 2014-11-19 |
MX2011013726A (es) | 2012-02-29 |
AU2010261342A1 (en) | 2012-01-19 |
CN102802624A (zh) | 2012-11-28 |
AR077155A1 (es) | 2011-08-03 |
EP2442805A1 (en) | 2012-04-25 |
US8778364B2 (en) | 2014-07-15 |
WO2010146606A1 (en) | 2010-12-23 |
EA201270050A1 (ru) | 2012-05-30 |
ZA201109510B (en) | 2012-09-26 |
EP2442805A4 (en) | 2012-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8778364B2 (en) | Nanodispersion of a drug and process for its preparation | |
CA2294337C (en) | Preparation of pharmaceutical compositions | |
TWI498329B (zh) | 神經激酶-1拮抗劑之靜脈注射劑型 | |
JP5937180B2 (ja) | ナノ分散体 | |
CA2442539C (en) | Method and composition for solubilising a biologically active compound with low water solubility | |
Apostolou et al. | The effects of solid and liquid lipids on the physicochemical properties of nanostructured lipid carriers | |
KR101890503B1 (ko) | 안구 장애의 치료를 위한 막-부착성 자가-조립된 시스템 | |
JP2011529042A (ja) | 安定した注射可能な水中油型ドセタキセルナノエマルション | |
WO1997030695A1 (en) | Drug delivery compositions suitable for intravenous injection | |
BR112012027279B1 (pt) | composições de emulsão farmacêutica com baixo teor de óleo que compreendem progestogênio | |
KR20010100194A (ko) | 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법 | |
CN102740833A (zh) | 吉西他滨衍生物的肠胃外制剂 | |
Abdelhakeem et al. | Lipid-based nano-formulation platform for eplerenone oral delivery as a potential treatment of chronic central serous chorioretinopathy: in-vitro optimization and ex-vivo assessment | |
US20120308663A1 (en) | Lipid nanocapsules, method for preparing same and use thereof as a drug | |
Utreja et al. | Lipoprotein-mimicking biovectorized systems for methotrexate delivery | |
WO2016113752A2 (en) | Liquid formulation of cabazitaxel | |
US20230165804A1 (en) | Solid lipid nanoparticle for intracellular release of active substances and method for production the same | |
CN102227210B (zh) | 亲脂性物质溶液,特别是药物溶液 | |
Tiemessen et al. | Characteristics of a novel phospholipid-based depot injectable technology for poorly water-soluble drugs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130109 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20131220 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140107 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140403 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140902 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140926 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5627039 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |